<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04948684</url>
  </required_header>
  <id_info>
    <org_study_id>CLEA-2021-167</org_study_id>
    <nct_id>NCT04948684</nct_id>
  </id_info>
  <brief_title>Efficacy of Botulinum Toxin for the Treatment of Dystonia Associated With Parkinson's Disease and Atypical Parkinsonism</brief_title>
  <official_title>Efficacy of Botulinum Toxin for the Treatment of Dystonia Associated With Parkinson's Disease and Atypical Parkinsonism: a Monocentric Cohort Study With Patient Reported Outcome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Avicenne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital Avicenne</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Dystonia is a disabling symptom affecting both patients with idiopathic Parkinson's disease&#xD;
      (PD) and atypical parkinsonism (AP).&#xD;
&#xD;
      Botulinum toxinum (BoNT), by blocking muscle contraction, is a possible treatment for focal&#xD;
      dystonia.&#xD;
&#xD;
      The benefit of BoNT treatment has been proven in some focal dystonia associated with PD or&#xD;
      AP.&#xD;
&#xD;
      The investigators aim to give an overview of the efficacy of BoNT in a variety of focal&#xD;
      dystonia in a large cohort of parkinsonian patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 1, 2017</start_date>
  <completion_date type="Actual">February 11, 2021</completion_date>
  <primary_completion_date type="Actual">February 11, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Comparison of the patient reported efficacy of botulinum toxin treatment between PD and AP patients</measure>
    <time_frame>Up to twelve months</time_frame>
    <description>Evaluation by the patient of the efficacy of the former injection on an improvement scale ranging from 0 to 100% (minimum value : 0, maximum value : 100, higher scores mean a better outcome) systematically made in routine care during follow up appointment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comparison of the patient reported duration of improvement after treatment by botulinum toxin between PD and AP patients</measure>
    <time_frame>Up to twelve months</time_frame>
    <description>Evaluation by the patient of the duration of the period during which symptoms were improved (in weeks) systematically made in routine care during follow up appointment</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Comparison of the patients' age between PD and AP groups</measure>
    <time_frame>Baseline</time_frame>
    <description>Age in years of patients from PD and AP groups</description>
  </other_outcome>
  <other_outcome>
    <measure>Comparison of the sex-ratio between PD and AP groups</measure>
    <time_frame>Screening</time_frame>
    <description>Percentage of female (%) in PD and AP groups</description>
  </other_outcome>
  <other_outcome>
    <measure>Comparison of the patients' duration of disease between PD and AP groups</measure>
    <time_frame>Baseline</time_frame>
    <description>Duration of the disease (years since diagnosis of PD or AP) of patients from PD and AP groups</description>
  </other_outcome>
  <other_outcome>
    <measure>Comparison of the patients' severity of the disease between PD and AP groups</measure>
    <time_frame>Baseline</time_frame>
    <description>Severity of the disease in both PD and AP groups measured by the Hoehn and Yahr scale (stage 0 to stage 5, a higher score meaning a more severe disease)</description>
  </other_outcome>
  <other_outcome>
    <measure>Comparison of the patients' daily need in levodopa between PD and AP groups</measure>
    <time_frame>Baseline</time_frame>
    <description>Levodopa equivalent daily dose (in mg, method as described by CL Tomlinson) of patient from PD and AP groups</description>
  </other_outcome>
  <other_outcome>
    <measure>Comparison of the percentage of patients treated with an apomorphine pump between PD and AP groups</measure>
    <time_frame>Baseline</time_frame>
    <description>Percentage of patients treated with apomorphine (%) in PD and AP groups</description>
  </other_outcome>
  <other_outcome>
    <measure>Comparison of the percentage of patients treated with deep brain stimulation between PD and AP groups</measure>
    <time_frame>Baseline</time_frame>
    <description>Percentage of patients treated with deep brain stimulation (%) in PD and AP groups</description>
  </other_outcome>
  <other_outcome>
    <measure>Comparison of the patients' age between patients presenting with dystonia and patients without reported dystonia</measure>
    <time_frame>Baseline</time_frame>
    <description>Age in years</description>
  </other_outcome>
  <other_outcome>
    <measure>Comparison of the percentage of patients treated with deep brain stimulation between patients presenting with dystonia and patients without reported dystonia</measure>
    <time_frame>Baseline</time_frame>
    <description>Percentage of patients treated with deep brain stimulation (%) in both groups</description>
  </other_outcome>
  <other_outcome>
    <measure>Comparison of the percentage of patients treated with an apomorphine pump between patients presenting with dystonia and patients without reported dystonia</measure>
    <time_frame>Baseline</time_frame>
    <description>Percentage of patients treated with apomorphine (%) in both groups</description>
  </other_outcome>
  <other_outcome>
    <measure>Comparison of the patients' daily need in levodopa between patients presenting with dystonia and patients without reported dystonia</measure>
    <time_frame>Baseline</time_frame>
    <description>Levodopa equivalent daily dose (in mg, method as described by CL Tomlinson) of patient from both groups</description>
  </other_outcome>
  <other_outcome>
    <measure>Comparison of the severity of the disease between patients presenting with dystonia and patients without reported dystonia</measure>
    <time_frame>Baseline</time_frame>
    <description>Severity of the disease in both groups measured by the Hoehn and Yahr scale (stage 0 to stage 5, a higher score meaning a more severe disease)</description>
  </other_outcome>
  <other_outcome>
    <measure>Comparison of the patients' duration of disease between patients presenting with dystonia and patients without reported dystonia</measure>
    <time_frame>Baseline</time_frame>
    <description>Duration of the disease (years since diagnosis of AP or PD) of patients</description>
  </other_outcome>
  <other_outcome>
    <measure>Comparison of the sex-ratio between patients presenting with dystonia and patients without reported dystonia</measure>
    <time_frame>Baseline</time_frame>
    <description>Percentage of female (%)</description>
  </other_outcome>
  <other_outcome>
    <measure>Comparison of the dystonia's characteristics between PD and AP groups : muscle affected</measure>
    <time_frame>Day 0</time_frame>
    <description>Muscle affected by dystonia (described with International Anatomical Terminology)</description>
  </other_outcome>
  <other_outcome>
    <measure>Comparison of the dystonia's characteristics between PD and AP groups : duration of dystonia</measure>
    <time_frame>Day 0</time_frame>
    <description>Duration of the dystonia (years since first report of the dystonia)</description>
  </other_outcome>
  <other_outcome>
    <measure>Comparison of the characteristics of the botulinum toxin injection between PD and AP groups : dose</measure>
    <time_frame>Day 0</time_frame>
    <description>Dose of BoNT used (in mL)</description>
  </other_outcome>
  <other_outcome>
    <measure>Comparison of the characteristics of the botulinum toxin injection between PD and AP groups : type of BoNT</measure>
    <time_frame>Day 0</time_frame>
    <description>Type of botulinum toxin used (onabotulinumtoxinA, abobotulinumtoxinA or incobotulinumtoxinA)</description>
  </other_outcome>
  <other_outcome>
    <measure>Comparison of the characteristics of the botulinum toxin injection between PD and AP groups : site of injection</measure>
    <time_frame>Day 0</time_frame>
    <description>Site of injection (described with International Anatomical Terminology)</description>
  </other_outcome>
  <other_outcome>
    <measure>Comparison of the characteristics of the botulinum toxin injection between PD and AP groups : number of injections</measure>
    <time_frame>Day 0</time_frame>
    <description>Number of injection performed during injection appointment</description>
  </other_outcome>
  <other_outcome>
    <measure>Comparison of the characteristics of the botulinum toxin injection between PD and AP groups : usage of electromyographic or ultrasound guidance</measure>
    <time_frame>Day 0</time_frame>
    <description>Usage of ultrasound or electromyography to guide BoNT injection</description>
  </other_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">63</enrollment>
  <condition>Parkinson Disease</condition>
  <condition>Atypical Parkinsonism</condition>
  <condition>Dystonia</condition>
  <arm_group>
    <arm_group_label>Patients with dystonia secondary to atypical Parkinsonism or Parkinson's disease</arm_group_label>
    <description>Patients with dystonia secondary to idiopathic Parkinson's disease or atypical parkinsonism and treated with BoNT</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients with atypical Parkinsonism or Parkinson's disease and no dystonia</arm_group_label>
    <description>Patients with idiopathic Parkinson's disease or atypical parkinsonism and without reported dystonia</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        All patients that have been evaluated in the Neurology department of Avicenne Hospital&#xD;
        (academic medical center) between september 1st 2017 and february 11th 2021.&#xD;
&#xD;
        Data will be retrospectively collected within the medical records of those patients.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosed Parkinson's disease or Atypical Parkinsonism&#xD;
&#xD;
          -  Age &gt; 18 years&#xD;
&#xD;
          -  Reported dystonia&#xD;
&#xD;
          -  At least 1 injection with Botulinum toxin realized&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Refusal to participate in the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bertrand Degos, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Avicenne</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Avicenne Hospital</name>
      <address>
        <city>Bobigny</city>
        <state>Seine-Saint-Denis</state>
        <zip>93009</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Dressler D. Botulinum toxin drugs: brief history and outlook. J Neural Transm (Vienna). 2016 Mar;123(3):277-9. doi: 10.1007/s00702-015-1478-1. Epub 2015 Nov 11. Review.</citation>
    <PMID>26559824</PMID>
  </reference>
  <reference>
    <citation>Jankovic J. Botulinum toxin: State of the art. Mov Disord. 2017 Aug;32(8):1131-1138. doi: 10.1002/mds.27072. Epub 2017 Jun 22. Review.</citation>
    <PMID>28639368</PMID>
  </reference>
  <reference>
    <citation>Tolosa E, Compta Y. Dystonia in Parkinson's disease. J Neurol. 2006 Dec;253 Suppl 7:VII7-13. Review.</citation>
    <PMID>17131231</PMID>
  </reference>
  <reference>
    <citation>Marsili L, Bologna M, Kojovic M, Berardelli A, Espay AJ, Colosimo C. Dystonia in atypical parkinsonian disorders. Parkinsonism Relat Disord. 2019 Sep;66:25-33. doi: 10.1016/j.parkreldis.2019.07.030. Epub 2019 Jul 23. Review.</citation>
    <PMID>31443953</PMID>
  </reference>
  <reference>
    <citation>Mills R, Bahroo L, Pagan F. An update on the use of botulinum toxin therapy in Parkinson's disease. Curr Neurol Neurosci Rep. 2015 Jan;15(1):511. doi: 10.1007/s11910-014-0511-3. Review.</citation>
    <PMID>25407133</PMID>
  </reference>
  <reference>
    <citation>Pacchetti C, Albani G, Martignoni E, Godi L, Alfonsi E, Nappi G. &quot;Off&quot; painful dystonia in Parkinson's disease treated with botulinum toxin. Mov Disord. 1995 May;10(3):333-6.</citation>
    <PMID>7651452</PMID>
  </reference>
  <reference>
    <citation>Giladi N, Meer J, Honigman S. The use of botulinum toxin to treat &quot;striatal&quot; toes. J Neurol Neurosurg Psychiatry. 1994 May;57(5):659.</citation>
    <PMID>8201355</PMID>
  </reference>
  <reference>
    <citation>Rieu I, Degos B, Castelnovo G, Vial C, Durand E, Pereira B, Simonetta-Moreau M, Sangla S, Fluchère F, Guehl D, Burbaud P, Geny C, Gayraud D, Ory-Magne F, Bouhour F, Llinares E, Derost P, Marques A, Durif F. Incobotulinum toxin A in Parkinson's disease with foot dystonia: A double blind randomized trial. Parkinsonism Relat Disord. 2018 Jan;46:9-15. doi: 10.1016/j.parkreldis.2017.10.009. Epub 2017 Oct 19.</citation>
    <PMID>29102441</PMID>
  </reference>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 6, 2021</study_first_submitted>
  <study_first_submitted_qc>June 24, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 2, 2021</study_first_posted>
  <last_update_submitted>June 24, 2021</last_update_submitted>
  <last_update_submitted_qc>June 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Avicenne</investigator_affiliation>
    <investigator_full_name>Arnaud Lapostolle</investigator_full_name>
    <investigator_title>interne</investigator_title>
  </responsible_party>
  <keyword>Botulinum toxinum</keyword>
  <keyword>Dystonia</keyword>
  <keyword>Parkinson Disease</keyword>
  <keyword>Atypical Parkinsonism</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
    <mesh_term>Dystonia</mesh_term>
    <mesh_term>Dystonic Disorders</mesh_term>
    <mesh_term>Parkinsonian Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

